American Epilepsy Society 63rd Annual Meeting

December 4-9, 2009; Boston, MA
Long-Term Safety and Tolerability of Lacosamide for Partial-Onset Seizures

The purpose of this study, presented as a poster at the annual AES meeting, was to examine the long-term safety of lacosamide (LCM) for partial-onset seizures based on all available data from Phase II-III double-blind and open-label extension trials. Read More>>

Efficacy and Tolerability of Levetiracetam

Levetiracetam extended release tablets (Keppra XR) became available in September 2008 for use as an add-on to other antiepileptic treatments for people with partial-onset seizures who are age 16 years and older. There are currently few data regarding the drug’s efficacy and tolerability. Read More>>

KONQUEST: Keppra versus Older Antiepileptic Drugs and Neuropsychiatric, Neurocognitive, and Quality-of-Life Outcomes in Treatment of Epilepsy as Substitution Monotherapy

Epilepsy, a chronic condition, has complex effects on a person’s social, vocational, and psychological function. Newer antiepileptic drugs (AEDs) such as levetiracetam (LEV) have been proposed to be better tolerated than older drugs such as carbamazepine (CBZ) and sodium valproate (VPA), therefore potentially improving quality of life. Read More>>